Targeting Alpha-Synuclein: Breakthroughs in the Quest to Halt Parkinson's Progression

The quest for a disease-modifying drug for Parkinson's disease continues - Drug Discovery and Development

Pharmaceutics, Free Full-Text

Pathological Pathways and Alpha-Synuclein in Parkinson's Disease: A View from the Periphery

IJMS, Free Full-Text

New hopes for disease modification in Parkinson's Disease - ScienceDirect

α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease

Failure of the ubiquitin–proteasome system in Parkinson's disease

PDF] The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease

Frontiers Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease

New alpha-synuclein structures could be targeted by Parkinson's therapies

IJMS, Free Full-Text

Pharmaceutics, Free Full-Text

Neuronal haemoglobin induces loss of dopaminergic neurons in mouse Substantia nigra, cognitive deficits and cleavage of endogenous α-synuclein

PDF) Alpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical Application

Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases - ScienceDirect